Supplement Clinical Trials Face Five Major Barriers

The 1994 Dietary Supplement Health and Education Act (DSHEA) defines and regulates dietary supplements in the United States. Under this act, supplements are treated as a category of food, not drugs, meaning they do not require FDA approval before being sold. This legislation allows the FDA to take action against unsafe or misbranded products only after they are already on the market. One significant issue is the potential for "overages," where manufacturers add more of a nutrient than the label states to ensure potency throughout the product's shelf life. For example, a USDA study of 54 adult multivitamin/mineral products found that the actual vitamin D content could range from 93% less to 172% more than the amount listed on the label. This variability makes it difficult for researchers to accurately measure nutrient intake in study participants. Creating a convincing placebo for a nutritional supplement trial is also a major hurdle, especially for food-based interventions where taste, texture, and smell are hard to replicate. The placebo effect itself can be powerful in nutrition studies; some trials have shown that participants' beliefs about what they are consuming can lead to measurable physiological changes, such as altered levels of the hunger hormone ghrelin. Participant adherence in supplement trials is often low, with studies showing compliance rates between 43% and 78% for treatments of chronic conditions. Common reasons for non-adherence include forgetfulness, adverse effects, and the belief that the supplement isn't important. This lack of adherence can compromise the validity of the trial's results. The endpoints used to measure a supplement's effectiveness are often less clear-cut than in pharmaceutical trials. While drug trials may look for specific clinical outcomes, supplement studies often assess more subtle effects on wellness, which can be harder to quantify. Furthermore, many trials are short-term, making it difficult to determine if any observed benefits translate to long-term health outcomes or disease prevention. Regulatory oversight for supplements varies significantly across the globe, with no international consensus on how these products should be defined or regulated. In the U.S., the number of dietary supplements on the market has grown from about 4,000 in 1994 to over 90,000. While the FDA can remove products deemed unsafe, this post-market enforcement means potential risks may not be identified until after products have been widely consumed.